VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO 2022 | COSMIC-313: cabozantinib with nivolumab and ipilimumab in untreated aRCC

Toni Choueiri, MD, Dana Farber Cancer Institute, Boston, MA, discusses the results of the Phase III COSMIC-313 study (NCT03937219), which assessed cabozantinib in combination with nivolumab and ipilimumab in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk. Cabozantinib and nivolumab with ipilimumab significantly improved progression-free survival versus in previously untreated aRCC. Safety was consistent with the known profiles of the treatment components, with follow-up for overall survival currently ongoing. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter